Human Papilloma VirusNCT07471113
Mobile App-Supported HPV and Breast Cancer Awareness Program
A study testing mobile application in people with Human Papilloma Virus and Breast Cancer, run by Ataturk University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this study is to learn about the impact of a mobile application-supported education program on women's HPV literacy and their beliefs regarding breast cancer screening. Read more about this study
- Who is it for?
- Ages 30 to 65 months, women onlyHealthy volunteers can take part
- Conditions the study is for
- Human Papilloma Virus, Breast Cancer, Women
- What is being tested?
- mobile application
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 Nov 2025to 2 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 months
- Women only
- Healthy volunteers accepted
- Child
Who may be able to join
- -Women aged 30-65 years
- -Literate (able to read and write)
- -Able to understand and speak Turkish
- -Able to use a smartphone
- -Willing to use the mobile application during the study period and consent to data sharing
Who cannot join
- Having undergone regular breast cancer (mammography) and/or cervical cancer (Pap smear/HPV DNA test) screening within the last 3 years, in accordance with national screening guidelines
- Previous diagnosis of any cancer
- Neurological conditions affecting cognitive function (e.g., dementia, Alzheimer's disease) or physical/psychiatric conditions that would seriously limit study participation and mobile app use
- Pregnancy or breastfeeding
- Participation in another health-related research study during the study period
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of a Mobile App-Supported Human Papilloma Virus and Breast Cancer Program on HPV Literacy and Breast Cancer Screening Beliefs
The goal of this study is to learn about the impact of a mobile application-supported education program on women's HPV literacy and their beliefs regarding breast cancer screening. The main questions it aims to answer are:
- Does a mobile application-supported program increase HPV literacy levels among women?
- Does this intervention strengthen women's positive beliefs and attitudes toward breast cancer screening? Researchers will examine how this holistic, health-based intervention changes participants' awareness and screening perspectives.
Read more
Participants will:
- Use a mobile application designed to provide education on HPV and breast cancer
- Complete surveys regarding their HPV knowledge and breast cancer screening beliefs before and after the program
- Engage with health-related content through the mobile platform for the duration of the study.
Read the detailed description
This study aims to evaluate the effect of a mobile application-supported Human Papillomavirus (HPV) and breast cancer program on HPV literacy and breast cancer screening beliefs among women attending primary health care services.
- Conditions
- Human Papilloma Virus, Breast Cancer, Women
- Being tested
- mobile application
- Keywords
- Human Papilloma Virus, Breast Cancer, Cervical Cancer, Nursing
- Medical subject headings
- Breast Neoplasms, Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mobile applicationBehavioural
A mobile application will be implemented for this group.
| Study group | Role | What they receive |
|---|---|---|
| Mobil-App | Experimental | A mobile application will be implemented as an intervention targeting this group. Receives: Behavioral: mobile application |
| Control | No intervention | No intervention will be made against this group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in HPV literacy (HPV-LS total score) from baseline (pretest) to post-intervention (posttest) compared between the Mobile Application-Supported Education Group and the Control Group.
The primary outcome is the change in participants' HPV literacy as measured by the HPV Literacy Scale (HPV; 24 items, 5-point Likert). Total scores range from 24 to 120, with higher scores indicating higher HPV literacy. The outcome will be assessed at baseline (pretest) and post-intervention (posttest) and compared between groups.
Measured: 12 MONTH
Change in breast cancer screening beliefs (Breast Cancer Screening Beliefs Scale total score and/or subscale scores) from baseline to post-intervention compared between groups.
Breast Cancer Screening Beliefs: The primary outcome is the change in breast cancer screening beliefs measured by the Breast Cancer Screening Beliefs Scale (13 items, 5-point Likert; transformed scoring 0-100). Higher scores indicate more positive screening beliefs (more favorable attitudes/knowledge and fewer perceived barriers). The outcome will be assessed at baseline (pretest) and post-intervention (posttest) and compared between groups.
Measured: 12 MONTH
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2026
- Study start2 Nov 2025
- Primary completion25 Dec 2025
- Study completion2 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human Papilloma VirusStudies of the same condition, open and under way.
- More trials run by Ataturk UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ataturk University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, NİHAN TÜRKOĞLU, Ataturk University
- Investigators
- Nihan Türkoğlu, Study director, Ataturk University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07471113
- Sponsor's protocol ID
- B.30.2.ATA.0.01.00/187 etik
- Status last verified
- Mar 2026
- First submitted
- 26 Nov 2025
- Last updated
- 13 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of a Mobile App-Supported Human Papilloma Virus and Breast Cancer Program on HPV Literacy and Breast Cancer Screening Beliefs
- ClinicalTrials.gov ID
- NCT07471113
- Acronym / sponsor ID
- B.30.2.ATA.0.01.00/187 etik
- Conditions
- Human Papilloma Virus, Breast Cancer, Women
- Keywords
- Human Papilloma Virus, Breast Cancer, Cervical Cancer, Nursing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Ataturk UniversityUniversity, hospital or other
- Study start
- 2 Nov 2025 (actual)
- Primary completion
- 25 Dec 2025 (actual)
- Study completion
- 2 Jan 2026 (actual)
- First posted
- 13 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to learn about the impact of a mobile application-supported education program on women's HPV literacy and their beliefs regarding breast cancer screening. The main questions it aims to answer are:
- Does a mobile application-supported program increase HPV literacy levels among women?
- Does this intervention strengthen women's positive beliefs and attitudes toward breast cancer screening? Researchers will examine how this holistic, health-based intervention changes participants' awareness and screening perspectives.
Participants will:
- Use a mobile application designed to provide education on HPV and breast cancer
- Complete surveys regarding their HPV knowledge and breast cancer screening beliefs before and after the program
- Engage with health-related content through the mobile platform for the duration of the study.
Detailed description
This study aims to evaluate the effect of a mobile application-supported Human Papillomavirus (HPV) and breast cancer program on HPV literacy and breast cancer screening beliefs among women attending primary health care services.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mobil-App | Experimental | Behavioral: mobile applicationA mobile application will be implemented as an intervention targeting this group. |
| Control | No intervention | –No intervention will be made against this group. |
Who may qualify
- Ages
- 30 to 65 months
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- -Women aged 30-65 years
- -Literate (able to read and write)
- -Able to understand and speak Turkish
- -Able to use a smartphone
- -Willing to use the mobile application during the study period and consent to data sharing
Key exclusion criteria (5 listed)
- Having undergone regular breast cancer (mammography) and/or cervical cancer (Pap smear/HPV DNA test) screening within the last 3 years, in accordance with national screening guidelines
- Previous diagnosis of any cancer
- Neurological conditions affecting cognitive function (e.g., dementia, Alzheimer's disease) or physical/psychiatric conditions that would seriously limit study participation and mobile app use
- Pregnancy or breastfeeding
- Participation in another health-related research study during the study period
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mobile applicationA mobile application will be implemented for this group. | Behavioural | Mobil-App |
Primary outcome
Change in HPV literacy (HPV-LS total score) from baseline (pretest) to post-intervention (posttest) compared between the Mobile Application-Supported Education Group and the Control Group.
Time frame: 12 MONTH
The primary outcome is the change in participants' HPV literacy as measured by the HPV Literacy Scale (HPV; 24 items, 5-point Likert). Total scores range from 24 to 120, with higher scores indicating higher HPV literacy. The outcome will be assessed at baseline (pretest) and post-intervention (posttest) and compared between groups.
Change in breast cancer screening beliefs (Breast Cancer Screening Beliefs Scale total score and/or subscale scores) from baseline to post-intervention compared between groups.
Time frame: 12 MONTH
Breast Cancer Screening Beliefs: The primary outcome is the change in breast cancer screening beliefs measured by the Breast Cancer Screening Beliefs Scale (13 items, 5-point Likert; transformed scoring 0-100). Higher scores indicate more positive screening beliefs (more favorable attitudes/knowledge and fewer perceived barriers). The outcome will be assessed at baseline (pretest) and post-intervention (posttest) and compared between groups.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Human Papilloma Virus
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Active, not recruiting
Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care
Human Papillomavirus Infection
Active, not recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
Cervical Carcinoma, Human Papillomavirus Infection
RecruitingObservational study
Natural History Study of GATA2 Deficiency and Related Disorders
GATA2 Deficiency
Recruiting
Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial
Human Papillomavirus-Related Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nihan Türkoğlu study director
Ataturk University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing mobile application in people with Human Papilloma Virus and Breast Cancer, run by Ataturk University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in HPV literacy (HPV-LS total score) from baseline (pretest) to post-intervention (posttest) compared between the Mobile Application-Supported Education Group and the Control Group. (time frame: 12 MONTH). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.